避免淋巴结阳性乳腺癌切除术后过度治疗与治疗不足:基因表达特征的应用是否已成熟?
综述讨论基因表达特征在淋巴结阳性、ER阳性/HER2阴性乳腺癌辅助化疗决策中的应用。Oncotype Dx、MammaPrint、Prosigna、EndoPredict和Breast Cancer Index等特征可不同程度识别未接受化疗而远处复发风险极低的淋巴结阳性患者,但长期随访数据仍待公布。正在进行的随机研究结果公布前,作者强调需高度谨慎,不当使用或误读这些转录组特征可能导致治疗不足并增加乳腺癌死亡率。
要点
- Oncotype Dx、MammaPrint、Prosigna、EndoPredict和Breast Cancer Index等特征可不同程度识别淋巴结阳性、未接受化疗而远处复发风险极低的患者。
- 淋巴结阳性患者中排除辅助化疗可能具有危害性,因该人群数据较淋巴结阴性者更有限。
- 正在进行的随机研究结果公布前,作者强调需高度谨慎,不当使用或误读转录组特征可能导致治疗不足并增加乳腺癌死亡率。
核心结论
- 正在进行的入组淋巴结阳性患者的随机研究结果公布前,作者强调需高度谨慎;不当使用和误读这些转录组特征可导致治疗不足,使腋窝淋巴结阳性患者暴露于不必要的风险,从而增加乳腺癌死亡率。
研究设计与样本
- 综述,批判性讨论临床实践中使用的基因表达特征相关可用数据,并给出ER阳性、HER2阴性、淋巴结阳性乳腺癌患者管理的实用建议。
主要发现
- 多项研究包括随机试验确立了某些基因表达特征在淋巴结阴性乳腺癌中的作用,因其预测的乳腺癌复发风险极低而可省略辅助化疗。
- 淋巴结阳性高危乳腺癌患者中可用数据更有限,排除辅助化疗可能具有危害性。
- 前瞻性-回顾性研究和有限的前瞻性数据显示,Oncotype Dx、MammaPrint、Prosigna、EndoPredict和Breast Cancer Index等特征以不同成功程度识别未接受化疗而远处复发风险极低的淋巴结阳性患者,但长期随访仍待公布。
临床怎么用
- 作者建议对ER阳性、HER2阴性、淋巴结阳性乳腺癌患者的管理给出实用建议,但原文摘要未列出具体推荐条款。
- 正在进行的入组淋巴结阳性患者的随机研究结果公布前,作者强调需高度谨慎。
局限性
- 淋巴结阳性高危乳腺癌患者中可用数据更有限。
- 长期随访仍待公布。
- 正在进行的入组淋巴结阳性患者的随机研究结果尚待公布。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prediction of benefit from adjuvant chemotherapy following resection of early breast cancer and, as a result, proper selection of candidates remains an elusive goal since the relative magnitude of benefit is the same regardless of the presence of clinicopathologic factors. Multiple studies, including randomized trials, establish the role of certain gene expression signatures in node-negative disease since they predict the risk of breast cancer relapse being so low that adjuvant chemotherapy can be omitted. In contrast, more limited data are available in higher risk, node-positive breast cancer patients, making the exclusion of adjuvant chemotherapy potentially hazardous. 'Prospective-retrospective' studies and limited prospective data show that several signatures, namely Oncotype Dx, MammaPrint, Prosigna, EndoPredict and Breast Cancer Index, select with different levels of success node-positive patients at very low risk for distant recurrence despite not receiving chemotherapy, although the long-term follow-up is still awaited. Pending, however the publication of the results from ongoing randomized studies which enroll patients with node-positive disease, major caution is warranted. Improper use and misinterpretation of these transcriptomic profiles can lead to undertreatment and exposure of patients to unnecessary risks resulting in increased breast cancer mortality for patients with axillary node-positive disease. With this review we critically discuss the available data on gene expression signatures that are used in clinical practice and offer practical recommendations regarding the management of patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive breast cancer.
引用
- Matikas A, Foukakis T, Swain S, et al. Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet? Ann Oncol. 2019. PMID: 31131397. doi:10.1093/annonc/mdz126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。